Reported 1 day ago
Piper Sandler has reiterated a Buy rating for Gossamer Bio Inc. (NASDAQ:GOSS), driven by the promising performance of its lead drug, Seralutinib, which targets pulmonary arterial hypertension. The stock has surged from around $1 to $2.50 this year, yielding nearly 180% returns. Analysts, including Yasmeen Rahimi and Patrick Trucchio, express confidence in Seralutinib's potential, citing positive Phase 2 trial results and upcoming pivotal trials as key catalysts for the company's future.
Source: YAHOO